Evaluation of Serum protein mass spectrometry technology to identify NSCLC patients with tumor response to gefitinib

摘要

@@ Objective To evaluate SELDI as a potential technique for predicting response to gefitinib in NSCLC patients. Methods 36 serum samples of NSCLC patients (13 men and 23 women) who had received SELDI-TOF-MS (surfaceenhanced laser desorption/ionization time-of-flight mass spectrometry technique) inspection before treatment with gefitinib (250mg/day) were evaluated. Patients were to have measureable disease and received gefitinib for >1 month. Patients were categorized into 3 groups according to tumor response RECIST (Response Evaluation Criteria In Solid Tumors) to gefitinib: efficacy group (CR+PR), stable group (SD) and inefficacy group (PD). The mass spectrums were analyzed by Biomarker Wizard 3.1 Software and Protein Chip 3.2.0 Software. The work proceeded in 3 sequential stages. In the first stage, 9 patients were categorized into the 3 groups after treatment with gefitinib and the differences between their protein fingerprint groups analyzed. In the second stage, patients were divided into groups considered suitable or not suitable for gefitinib and the imprecise effect group according to the protein fingerprints identified in the first stage, so as to verify the coincidence between standardized fingerprints and clinical response. The third stage provided further confirmation of the relationship between fingerprint curve shape and its dynamic change and the response to gefitinib based on the findings from the first stage.